The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 14, 2015

Filed:

Nov. 08, 2013
Applicants:

Mildred Enid Acevedo-duncan, Plant City, FL (US);

Hla Y. Win, Tampa, FL (US);

Raoul Salup, Tampa, FL (US);

Inventors:

Mildred Enid Acevedo-Duncan, Plant City, FL (US);

Hla Y. Win, Tampa, FL (US);

Raoul Salup, Tampa, FL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/713 (2006.01); A61K 9/127 (2006.01); A61K 31/7105 (2006.01); C12N 15/113 (2010.01); G01N 33/574 (2006.01); A61K 31/675 (2006.01);
U.S. Cl.
CPC ...
A61K 31/713 (2013.01); A61K 9/127 (2013.01); A61K 31/675 (2013.01); A61K 31/7105 (2013.01); C12N 15/1137 (2013.01); C12Y 207/11013 (2013.01); G01N 33/57434 (2013.01); C12N 2310/14 (2013.01); G01N 2800/56 (2013.01); Y10T 436/25 (2015.01);
Abstract

A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-ι and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-ι, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-ι levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-ι. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-ι. The compound can be a small interfering RNA (siRNA) molecule.


Find Patent Forward Citations

Loading…